Psilocybin for Treatment-Resistant Depression (NCT06230757) | Clinical Trial Compass
CompletedPhase 2
Psilocybin for Treatment-Resistant Depression
United States20 participantsStarted 2024-07-08
Plain-language summary
The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
Who can participate
Age range
21 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
. Recent acute myocardial infarction or evidence of ischemia
. Malignant hypertension
. Congenital long QT syndrome
. Acute renal failure
. Severe hepatic impairment
. Respiratory failure
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial focused on measuring changes in anhedonia — that feeling of not being able to enjoy things — using a specific rating scale. Given that my main symptoms include treatment-resistant depression, how much of my struggle would you say is driven by anhedonia, and would that make this kind of research relevant to my situation?
2Since this was a Phase 2 trial and it has already completed, what does that mean for what we actually know about psilocybin's safety and effectiveness for treatment-resistant depression — and is there any published data from this study we could look at together?
3Psilocybin-assisted therapy typically requires supervised sessions and psychological support before, during, and after treatment. Before even considering something like this, how does that kind of commitment compare to other options we haven't tried yet for my treatment-resistant depression?
4Because this trial is completed and no longer enrolling, are there other active psilocybin or psychedelic-assisted therapy trials I might be eligible for, or are there clinics offering this kind of treatment outside of a trial setting that you'd consider legitimate?
5Given that I've already tried multiple treatments without enough relief, how would you weigh the still-emerging evidence behind psilocybin against more established next-step options like ECT, ketamine, or MAOIs for someone in my situation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change from baseline in self-reported anhedonia scores on the Dimensional Anhedonia Rating Scale (DARS).